OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

被引：47

作者：

Andtbacka, Robert Hans Lngemar

Collichio, Frances A.

Amatruda, Thomas

Senzer, Neil N.

Chesney, Jason

Delman, Keith A.

Spitler, Lynn E.

Puzanov, Igor

Coleman, Susan

Ye, Yining

Vanderwalde, An M.

Coffin, Robert

Kaufman, Howard

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA

[3] Hubert H Humphrey Canc Ctr, Robbinsdale, MN USA

[4] Mary Crowley Canc Res Ctr, Dallas, TX USA

[5] Univ Louisville, Louisville, KY 40292 USA

[6] Emory Univ, Dept Surg, Atlanta, GA 30322 USA

[7] Northern Calif Melanoma Ctr, San Francisco, CA USA

[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[9] Amgen Inc, Woburn, MA USA

[10] Amgen Inc, Dept Biostat & Epidemiol, San Francisco, CA USA

[11] Amgen Inc, Thousand Oaks, CA 91320 USA

[12] Rush Univ, Med Ctr, Chicago, IL 60612 USA

来源：

关键词：

D O I：

10.1200/jco.2013.31.18_suppl.lba9008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA9008

引用

页数：1